Key result
Transplacental treatment with digoxin and flecainide successfully controlled fetal supraventricular tachycardia with hydrops, demonstrating that therapeutic drug monitoring is necessary as maternal serum concentrations fluctuate during the third trimester.
Why the study?
Maternal serum concentrations of digoxin and flecainide may fluctuate throughout the third trimester during transplacental therapy, making therapeutic drug monitoring potentially effective to improve treatment efficacy and safety.
Case Report (n=1)
No
Therapeutic drug monitoring of maternal serum concentrations of digoxin and flecainide during the third trimester may help optimize transplacental treatment of fetal SVT with hydrops by balancing efficacy and maternal tolerability.
May support flecainide TDM to balance fetal SVT control and maternal tolerability; hypothesis-generating, should not yet change practice.
When transplacental therapy is conducted, the maternal serum concentrations of digoxin and flecainide may fluctuate throughout third trimester. Therefore, TDM may be effective in improving the efficacy and safety of treatment.
No takes yet. Share an insight, caveat, or question.
Takatsuka et al. (2021) conducted a case report in Fetal supraventricular tachycardia with hydrops (n=1). Digoxin and flecainide was evaluated on Fetal heart rate and maternal serum drug concentrations. Transplacental treatment with digoxin and flecainide successfully controlled fetal supraventricular tachycardia with hydrops, demonstrating that therapeutic drug monitoring is necessary as maternal serum concentrations fluctuate during the third trimester.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: